Y-mAbs, in distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab

 

• Y-mAbs Therapeutics (YMAB -0.4%) and Takeda Pharmaceutical (TAK +1.4%) have entered into an exclusive license and distribution agreement in Israel, for Danyelza for the treatment of relapsed/refractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
• DANYELZA (naxitamab-gqgk) was approved by the FDA recently. Additionally, Y-mAbs plans to resubmit the amended marketing application for omburtamab to the FDA by this year or in early 2021.
• Financial details were not disclosed.
• https://seekingalpha.com/news/3641765-y-mabs-inks-distribution-pact-takeda-for-nerve-cell-cancer-meds-danyelza-omburtamab